Four Areas of Engagement Requiring Strengthening in Modern Proteomics Today.

Forskningsoutput: TidskriftsbidragDebate/Note/Editorial

Standard

Four Areas of Engagement Requiring Strengthening in Modern Proteomics Today. / Fehniger, Thomas; Boja, Emily S; Rodriguez, Henry; Baker, Mark S; Marko-Varga, György.

I: Journal of Proteome Research, Vol. 13, Nr. 12, 2014, s. 5310-5318.

Forskningsoutput: TidskriftsbidragDebate/Note/Editorial

Harvard

APA

CBE

MLA

Vancouver

Author

Fehniger, Thomas ; Boja, Emily S ; Rodriguez, Henry ; Baker, Mark S ; Marko-Varga, György. / Four Areas of Engagement Requiring Strengthening in Modern Proteomics Today. I: Journal of Proteome Research. 2014 ; Vol. 13, Nr. 12. s. 5310-5318.

RIS

TY - JOUR

T1 - Four Areas of Engagement Requiring Strengthening in Modern Proteomics Today.

AU - Fehniger, Thomas

AU - Boja, Emily S

AU - Rodriguez, Henry

AU - Baker, Mark S

AU - Marko-Varga, György

PY - 2014

Y1 - 2014

N2 - The global human proteomics community in 2014 is fully engaged in projects that aim to create a better understanding of human biology and its complexities and to provide products from this new knowledge that will in some way benefit humanity. Human proteomics, like any other scientific enterprise, needs to identify areas of direction and development, both for the near future in completing current research projects and into the long-term for the engagement with even more complex challenges. In this Editorial we highlight and discuss four important areas that we collectively believe require attention and demand a collective response going forward. These four areas are: (1) Provide high-quality standardized, sensitive, specific, quantitative, and readily accessible protein, peptide, or other biomarkers of health, disease, response to therapy into the approval processes of regulatory agencies (e.g., U.S. Food and Drug Administration; FDA), and obtaining approval from the relevant agencies for their use in a clinical or other testing settings. (2) Implement standard processes for collecting, processing, and storing human clinical samples in biorepositories and enforcement of measures to ensure subject integrity including informed consent for the downstream use of samples and in registrations of subject identities within study databases. (3) Test and validate mass spectrometry technology platforms that hold much promise for creating opportunities for obtaining new important knowledge at levels of detection previously not achievable. (4) Organize clinical discovery operations and activities in an intuitive manner to meet the challenges of increased interests in the science we provide and diminishing levels of centrally financed resource and infrastructure support.

AB - The global human proteomics community in 2014 is fully engaged in projects that aim to create a better understanding of human biology and its complexities and to provide products from this new knowledge that will in some way benefit humanity. Human proteomics, like any other scientific enterprise, needs to identify areas of direction and development, both for the near future in completing current research projects and into the long-term for the engagement with even more complex challenges. In this Editorial we highlight and discuss four important areas that we collectively believe require attention and demand a collective response going forward. These four areas are: (1) Provide high-quality standardized, sensitive, specific, quantitative, and readily accessible protein, peptide, or other biomarkers of health, disease, response to therapy into the approval processes of regulatory agencies (e.g., U.S. Food and Drug Administration; FDA), and obtaining approval from the relevant agencies for their use in a clinical or other testing settings. (2) Implement standard processes for collecting, processing, and storing human clinical samples in biorepositories and enforcement of measures to ensure subject integrity including informed consent for the downstream use of samples and in registrations of subject identities within study databases. (3) Test and validate mass spectrometry technology platforms that hold much promise for creating opportunities for obtaining new important knowledge at levels of detection previously not achievable. (4) Organize clinical discovery operations and activities in an intuitive manner to meet the challenges of increased interests in the science we provide and diminishing levels of centrally financed resource and infrastructure support.

U2 - 10.1021/pr500472d

DO - 10.1021/pr500472d

M3 - Debate/Note/Editorial

VL - 13

SP - 5310

EP - 5318

JO - Journal of Proteome Research

T2 - Journal of Proteome Research

JF - Journal of Proteome Research

SN - 1535-3893

IS - 12

ER -